Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease

Clinical Nephrology

Volumn 77, Issue 3, 2012, Pages 171-181

  Martinez Vea, Alberto ^a   Marcas, Luis ^a   Bardají, Alfredo ^a   Romeu, Marta ^b   Gutierrez, Cristina ^a   García, Carmen ^a   Compte, Teresa ^c   Nogues, Rosa ^a   Peralta, Carmen ^a   Giralt, Montserrat ^b  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c Nephrology Assistance Unit   (Spain)

Author keywords

Anemia; Chronic kidney disease; Erythropoietin; Left ventricular hypertrophy; Oxidative stress

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN; OXIDIZED LOW DENSITY LIPOPROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; BIOLOGICAL MARKER; ERYTHROPOIETIN; GLUTATHIONE DISULFIDE; LOW DENSITY LIPOPROTEIN; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; CHRONIC DISEASE; DRUG EFFECT; ECHOGRAPHY; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; ANEMIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; ERYTHROPOIETIN; FEMALE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; LIPOPROTEINS, LDL; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859506412     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107309     Document Type: Article

References (48)

1. Kao MP, Ang DS, Pall A, Struthers AD. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens. 2010; 24: 1-8. doi:10.1038/jhh.2009.70 PubMed
2. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006; 48: 752-760. doi:10.1053/j.ajkd. 2006.08.015 PubMed
3. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in endstage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003; 18: 1272-1280. doi:10.1093/ndt/gfg074 PubMed
4. Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei BL, van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF. Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract. 2004; 98: c3-c7. doi:10.1159/000079921 PubMed
5. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. Semin Dial. 2009; 22: 405-408. doi:10.1111/j.1525- 13 9X. 2009.00590.x PubMed
6. Alhamdani MS. Impairment of glutathione biosynthetic pathway in uraemia and dialysis. Nephrol Dial Transplant. 2005; 20: 124-128. doi: 10. 1093/ndt/gfh569 PubMed
7. Romeu M, Nogués R, Marcas L, Sánchez-Martos V, Mulero M, Martinez-Vea A, Mallol J, Giralt M. Evaluation of oxidative stress biomarkers in patients with chronic renal failure: a case control study. BMC Res Notes. 2010; 3: 20. doi:10. 11 86/1756-0500-3-20 PubMed
8. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart. 2007; 93: 903-907. doi:10.1 1 36/hrt.2005.068270 PubMed
9. Annuk M, Zilmer M, Lind L, Linde T, Fellström B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001; 12: 2747-2752. PubMed
10. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007; 49: 241-248. doi:10.1161/01.HYP. 00 00254415.31362.a7 PubMed
11. Lahera V, Goicoechea M, de Vinuesa SG, Oubiña P, Cachofeiro V, Gómez-Campderá F, Amann R, Luño J. Oxidative stress in uremia: the role of anemia correction. J Am Soc Nephrol. 2006; 17 (Suppl 3): S174-S177. doi:10.1681/ASN.2006 08 0911 PubMed
12. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996; 27: 347-354. doi:10. 1016/S0272-6386(96)90357-1 PubMed
13. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999; 34: 125-134. doi:10.1016/S0272-6386(99)70118-6 PubMed
14. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M. Antioxidative effects of erythropoietin. Kidney Int Suppl. 2007; 72: S10-S15. doi:10.1038/ sj.ki.5002482 PubMed
15. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a metaanalysis. Clin J Am Soc Nephrol. 2009; 4: 755-762. doi:10.2215/CJN.02730608 PubMed
16. Marsillach J, Martínez-Vea A, Marcas L, Mackness B, Mackness M, Ferré N, Joven J, Camps J. Administration of exogenous erythropoietin β affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin Exp Pharmacol Physiol. 2007; 34: 347-349. doi:10.11 11 /j.1440-1681.2007.04552.x PubMed
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41. doi:10.1159/000180580 PubMed
18. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem. 1976; 74: 214-226. doi:10.1016/0003-2697(76)90326-2 PubMed
19. Wheeler CR, Salzman JA, Elsayed NM, Omaye ST, Korte DW Jr. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. Anal Biochem. 1990; 184: 193-199. doi:10.1016/0003-2697(90) 9 0668-Y PubMed
20. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 1996; 76: 663-669. PubMed
21. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978; 58: 1072-1083. PubMed
22. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux RB, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989; 2: 358-367. PubMed
23. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20: 1251-1260. doi:10.1016/0735-1097 (92) 90385-Z PubMed
24. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995; 25: 1056-1062. doi:10.1016/0735-1097(94)00540-7 PubMed
25. Pombo JF, Troy BL, Russell RO Jr. Left ventricular volumes and ejection fraction by echocardiography. Circulation. 1971; 43: 480-490. PubMed
26. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001; 12: 2759-2767. PubMed
27. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007; 116: 85-97. doi:10.1161/CIRCULATIONAHA. 106.678342 PubMed
28. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47: 186-192. doi:10.1038/ki.1995.22 PubMed
29. Nardi E, Palermo A, Mulè G, Cusimano P, Cottone S, Cerasola G. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens. 2009; 27: 633-641. doi:10.1097/HJH.0b013e3283220ecd PubMed
30. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000; 35: 250-256. doi:10.1016/S0272-6386(00)70334-9 Pub Med
31. Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luño J; Spanish Group for the Study of the Anemia and Left Ventricular Hypertrophy in Pre-dialysis Patients. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin < 10 g/dl. Kidney Int. 2005; 68: 788-795. doi:10.1111/j.1523-1755.2005. 00458.x PubMed
32. Levin A, Djurdjev O, Thompson CR, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005; 46: 799-811. doi:10.1053/j. ajkd.2005.08.007 PubMed
33. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16: 2180-2189. doi:10.1681/ASN.2004121039 PubMed
34. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084. doi:10.1056/NEJMoa062276 Pub Med
35. de Francisco ALM. Individualizing anaemia therapy. NDT Plus. 2010; 3: 519-526. doi:10.1093/ ndtplus/sfq164
36. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010; 25: 2846-2850. doi:10.1093/ ndt/gfq336 PubMed
37. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005; 46: 320-327. doi:10.1053/j.ajkd.2005 .04. 031 PubMed
38. Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, Zaug MF, Burger HU, Drueke TB. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol. 2009; 20: 2651-2660. doi:10.1681/ASN.2009060631 PubMed
39. Patel RK, Oliver S, Mark PB, Powell JR, Mc-Quarrie EP, Traynor JP, Dargie HJ, Jardine AG. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin J Am Soc Nephrol. 2009; 4: 1477-1483. doi:10.2215/CJ N.03350509 PubMed
40. Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco RL, Homma S, Di Tullio MR. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008; 101: 1787-1791. doi:10.1016/j.amjcard. 20 0 8.02.082 PubMed
41. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006; 52: 601-623. doi:10.1373/clinchem.2005.061408 PubMed
42. Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC, Vaccarino V, Harrison DG, Quyyumi AA. The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J Am Coll Cardiol. 2006; 47: 1005-1011. doi:10.1016/j. jacc.2005.09.063 PubMed
43. Gu M, Love H, Schofield D, Turkie W, Odom N, Braganza JM. A pilot study of blood antioxidant and free radical marker profiles in patients awaiting coronary artery bypass grafting. Clin Chim Acta. 1996; 252: 181-195. doi:10.1016/0009-898 1(96)06333-4 PubMed
44. Shimizu H, Kiyohara Y, Kato I, Kitazono T, Tanizaki Y, Kubo M, Ueno H, Ibayashi S, Fujishima M, Iida M. Relationship between plasma glutathione levels and cardiovascular disease in a defined population: the Hisayama study. Stroke. 2004; 35: 2072-2077. doi:10.1161/01.STR.000013 8022. 86 5 09.2d PubMed
45. Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J, Willerson JT, Betocchi S, Wickline SA, Efimov IR, Marian AJ. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation. 2009; 119: 1398-1407. doi:10.1161/CIRCULATION AHA. 108.790501 PubMed
46. Shiomi T, Tsutsui H, Matsusaka H, Murakami K, Hayashidani S, Ikeuchi M, Wen J, Kubota T, Utsumi H, Takeshita A. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation. 2004; 109: 544-549. doi:10. 1161/01.CIR.0000109701.77059.E9 PubMed
47. Sekhar RV, McKay SV, Patel SG, Guthikonda AP, Reddy VT, Balasubramanyam A, Jahoor F. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care. 2011; 34: 162-167. doi:10.2337/dc10-1006 PubMed
48. Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res. 2004; 43: 200-227. doi:10.1016/j.plipres.2003.10.001 PubMed